Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Donna E. Reece, MD, Madeline Phillips, BAS, Beryl Chung, Christine I. Chen, MD, Esther Masih-Khan, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3231.

https://doi.org/10.1182/blood.V122.21.3231.3231

Published: 2013

Journal Articles

Long-Term Survival With Cybord Induction Therapy In Newly Diagnosed Multiple Myeloma

Craig B. Reeder, MD, Donna E. Reece, MD, Vishal Kukreti, MD, FRCPC, Joseph Mikhael, MD, Christine I. Chen, MD, Suzanne Trudel, MD, Kristina Laumann, Joseph Hentz, Giovani Piza, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Jose F Leis, MD, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Jacy Spong, BS, RN, BSN, Angela Mayo, PA/NP, Keith Stewart, MD

Blood (2013) 122 (21): 3192.

https://doi.org/10.1182/blood.V122.21.3192.3192

Published: 2013

Journal Articles

Follicular Lymphoma In Young Adults: Clinical Characteristics and Early Treatment Outcomes

Shane A Gangatharan, MBBS, FRACP, FRCPA, John Kuruvilla, MD, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Mary Gospodarowicz, MD, David C. Hodgson, MD, Alex Sun, MD, Richard Tsang, MD, Manjula Maganti, Melania Pintilie, Michael Crump, MD FRCPC

Blood (2013) 122 (21): 4273.

https://doi.org/10.1182/blood.V122.21.4273.4273

Published: 2013

Journal Articles

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

Donna E. Reece, MD, Madeline Phillips, BAS, Christine I. Chen, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5378.

https://doi.org/10.1182/blood.V122.21.5378.5378

Published: 2013

Journal Articles

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Craig Reeder, MD, Stephen M Ansell, M.D., Ph.D., Katherine Gano, Amylou C. Dueck, PhD, Christopher Conley, MD, Grzegorz S. Nowakowski, Kelly Curtis, MD, John Camoriano, MD, Jose Leis, MD, PhD, James L Slack, MD, Riccardo Valdez, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Keith Stewart, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2741.

https://doi.org/10.1182/blood.V120.21.2741.2741

Published: 2012

Journal Articles

RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells,

James M Bogenberger, PhD, Chang-Xin Shi, Irma Gonzales, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Pierre Noel, MD, James L. Slack, MD, Ruben A. Mesa, MD, Keith Stewart, MBA, MB, CHB, Yihua Qiu, Kevin R Coombes, Steven M. Kornblau, MD, David Azorsa, PhD, Raoul Tibes, MD, PhD

Blood (2011) 118 (21): 3513.

https://doi.org/10.1182/blood.V118.21.3513.3513

Published: 2011

Journal Articles

Comparative Genomic Hybridization, Gene Expression Profiling and Whole Genome Sequencing Analysis of Disease Progression in Myeloma Reveals Vigorous Clonal Evolution in Patients with High Baseline Genetic Risk.

Jan Egan, PhD, Jonathan J Keats, PhD, P. Leif Bergsagel, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, John Carpten, A. Keith Stewart, MD

Blood (2009) 114 (22): 2810.

https://doi.org/10.1182/blood.V114.22.2810.2810

Published: 2009

Journal Articles

Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.

Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Yuan Xiao Zhu, Jessica Schmidt, BS, Hongwei Yin, PhD, Quick Que, PhD, David Azorsa, PhD, Louise M. Perkins, PhD, Esteban Braggio, PhD, Craig B. Reeder, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Spyro Mousses, PhD, A. Keith Stewart, MD

Blood (2009) 114 (22): 601.

https://doi.org/10.1182/blood.V114.22.601.601

Published: 2009

Journal Articles

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

Yuan Xiao Zhu, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Chang-Xin Shi, PhD, Jessica Schmidt, BS, Laura Bruins, Jonathan J Keats, PhD, Holly Yin, PhD, Chris Sereduk, Spyro Mousses, PhD, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 602.

https://doi.org/10.1182/blood.V114.22.602.602

Published: 2009

Journal Articles

A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.

Craig B. Reeder, MD, Donna E. Reece, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Christine Chen, MD, Suzanne Trudel, MD, Kristina Laumann, Joseph Hentz, Nick Pirooz, Jg Piza, MD, Victor J Jimenez Zepeda, Rafael Fonseca, P. Leif Bergsagel, Jose Leis, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 616.

https://doi.org/10.1182/blood.V114.22.616.616

Published: 2009

Journal Articles

Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening.

Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Yuan Xiao Zhu, Jessica Schmidt, BS, Chang-Xin Shi, Hongwei Yin, PhD, Spyro Mousses, PhD, A. Keith Stewart, MD

Blood (2009) 114 (22): 2801.

https://doi.org/10.1182/blood.V114.22.2801.2801

Published: 2009

Journal Articles

Identification of a Potent Natural Triterpenoid Inhibitor of Proteosome Chymotrypsin-Like Activity and NF-κB with Specific Anti-Myeloma Activity in Vitr o and in Vivo

Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Jonathan J Keats, PhD, Jessica Schmidt, BS, Chang-Xin Shi, Yuan X Zhu, PhD, Xinliang Mao, MD, PhD, Aaron D. Schimmer, Keith Stewart, MD

Blood (2008) 112 (11): 3679.

https://doi.org/10.1182/blood.V112.11.3679.3679

Published: 2008

NARROW

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Long-Term Survival With Cybord Induction Therapy In Newly Diagnosed Multiple Myeloma

Follicular Lymphoma In Young Adults: Clinical Characteristics and Early Treatment Outcomes

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells,

Comparative Genomic Hybridization, Gene Expression Profiling and Whole Genome Sequencing Analysis of Disease Progression in Myeloma Reveals Vigorous Clonal Evolution in Patients with High Baseline Genetic Risk.

Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.

Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening.

Identification of a Potent Natural Triterpenoid Inhibitor of Proteosome Chymotrypsin-Like Activity and NF-κB with Specific Anti-Myeloma Activity in Vitr o and in Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only